An anonymous reader shares a report: The Food and Drug Administration has refused to start a review of Moderna's application for its experimental flu shot, the company announced Tuesday, in another sign of the Trump administration's influence on tightening vaccine regulations in the U.S. Moderna said the move is inconsistent with previous feedback from the agency from before it submitted the application and started phase three trials on the shot, called mRNA-1010. The drugmaker said it has requested a meeting with the FDA to "understand the path forward." Moderna noted that the agency did not identify any specific safety or efficacy issues with the vaccine, but instead objected to the study design, despite previously approving it. The company added that the move won't impact its 2026 financial guidance. Moderna's jab showed positive phase three data last year, meeting all of the trial goals. At the time, Moderna said the stand-alone flu shot was key to its efforts to advance a combination vaccine targeting both influenza and Covid-19.

Read more of this story at Slashdot.

As Super Bowl Sunday comes to a close, America's National Football League "is challenging innovators to improve the facemask on football helmets to reduce concussions in the game," reports the Associated Press: The league announced on Friday at an innovation summit for the Super Bowl the next round in the HealthTECH Challenge series, a crowdsourced competition designed to accelerate the development of cutting-edge football helmets and new standards for player safety. The challenge invites inventors, engineers, startups, academic teams and established companies to improve the impact protection and design of football helmets through improvements to how facemasks absorb and reduce the effects of contact on the field... Most progress on helmet safety has come from improvements to the shell and padding, helping to reduce the overall rate of concussions. Working with the helmet industry, the league has brought in position-specific helmets, with those for quarterbacks, for example, having more padding in the back after data showed most concussions for QBs came when the back of the head slammed to the turf. But the facemask has mostly remained the same. This past season, 44% of in-game concussions resulted from impact to the player's facemask, up from 29% in 2015, according to data gathered by the NFL. "What we haven't seen over that period of time are any changes of any note to the facemask," [said Jeff Miller, the NFL's executive vice president overseeing player health and safety]... "Now we see, given the changes in our concussion numbers and injuries to players, that as changes are made to the helmet, fewer and fewer concussions are caused by hits to the shell, and more and more concussions as a percentage are by hits to the facemask..." Selected winners will receive up to $100,000 in aggregate funding, as well as expert development support to help move their concepts from the lab to the playing field. Winners will be announced in August, according to the article, "and Miller said he expected helmet manufacturers to start implementing any improvements into helmets soon after that."

Read more of this story at Slashdot.

"After a half-century asking us to exercise more, doctors and physiologists say we have been thinking about it wrong," writes Washington Post columnist Michael J. Coren. "U.S. and World Health Organization guidelines no longer specify a minimum duration of moderate or vigorous aerobic activity." Movement-tracking studies show even tiny, regular bursts of effort — as short as 30 seconds — can capture many of the health benefits of the gym. Climbing two to three flights of stairs a few times per day could change your life. Experts call it VILPA, or vigorous intermittent lifestyle physical activity. "The message now is that all activity counts," said Martin Gibala, a professor and former chair of the kinesiology department at McMaster University in Canada... Just taking the stairs daily is associated with lower body weight and cutting the risk of stroke and heart disease — the leading (and largely preventable) cause of death globally. While it may not burn many calories (most exercise doesn't), it does appear to extend your health span. Leg power — a measure of explosive muscle strength — was a stronger predictor of brain aging than any lifestyle factors measured in a 2015 study in the journal Gerontology... How little activity can you do? Four minutes daily. Essentially, a few flights of stairs at a vigorous pace. That's the effort [Emmanuel Stamatakis, a professor of physical activity and population health at the University of Sydney] found delivered significant health benefits in that 2022 study of British non-exercisers. "We saw benefits from the first minute," Stamatakis said. For Americans, the effect is even more dramatic: a 44 percent drop in deaths, according to a peer-reviewed paper recently accepted for publication. "We showed for the first time that vigorous intensity, even if it's done as part of the day-to-day routine, not in a planned and structured manner, works miracles," Stamatakis said. "The key principle here is start with one, two minutes a day. The focus should be on making sure that it's something that you can incorporate into your daily routine. Then you can start thinking about increasing the dose." Intensity is the most important factor. You won't break a sweat in a brief burst, but you do need to feel it. A highly conditioned athlete might need to sprint to reach vigorous territory. But many people need only to take the stairs. Use your breathing as a guide, Stamatakis said: If you can sing, it's light intensity. If you can speak but not sing, you're entering moderate exertion. If you can't hold a conversation, it's vigorous. The biggest benefits come from moderate to vigorous movement. One minute of incidental vigorous activity prevents premature deaths, heart attacks or strokes as well as about three minutes of moderate activity or 35 to 49 minutes of light activity.

Read more of this story at Slashdot.

An anonymous reader quotes a report from Wired: About a decade ago, many media outlets -- including WIRED -- zeroed in on a weird trend at the intersection of mental health, drug science, and Silicon Valley biohacking: microdosing, or the practice of taking a small amount of a psychedelic drug seeking not full-blown hallucinatory revels but gentler, more stable effects. Typically using psilocybin mushrooms or LSD, the archetypal microdoser sought less melting walls and open-eye kaleidoscopic visuals than boosts in mood and energy, like a gentle spring breeze blowing through the mind. Anecdotal reports pitched microdosing as a kind of psychedelic Swiss Army knife, providing everything from increased focus to a spiked libido and (perhaps most promisingly) lowered reported levels of depression. It was a miracle for many. Others remained wary. Could 5 percent of a dose of acid really do all that? A new, wide-ranging study by an Australian biopharma company suggests that microdosing's benefits may indeed be drastically overstated -- at least when it comes to addressing symptoms of clinical depression. A Phase 2B trial of 89 adult patients conducted by Melbourne-based MindBio Therapeutics, investigating the effects of microdosing LSD in the treatment of major depressive disorder, found that the psychedelic was actually outperformed by a placebo. Across an eight-week period, symptoms were gauged using the Montgomery-Asberg Depression Rating Scale (MADRS), a widely recognized tool for the clinical evaluation of depression. The study has not yet been published. But MindBio's CEO Justin Hanka recently released the top-line results on his LinkedIn, eager to show that his company was "in front of the curve in microdosing research." He called it "the most vigorous placebo controlled trial ever performed in microdosing." It found that patients dosed with a small amount of LSD (ranging from 4 to 20g, or micrograms, well below the threshold of a mind-blowing hallucinogenic dose) showed observable upticks in feelings of well-being, but worse MADRS scores, compared to patients given a placebo in the form of a caffeine pill. (Because patients in psychedelic trials typically expect some kind of mind-altering effect, studies are often blinded using so-called "active placebos," like caffeine or methylphenidate, which have their own observable psychoactive properties.) This means, essentially, that a medium-strength cup of coffee may prove more beneficial in treating major depressive disorder than a tiny dose of acid. Good news for habitual caffeine users, perhaps, but less so for researchers (and biopharma startups) counting on the efficacy of psychedelic microdosing. "It's probably a nail in the coffin of using microdosing to treat clinical depression," Hanka says. "It probably improves the way depressed people feel -- just not enough to be clinically significant or statistically meaningful."

Read more of this story at Slashdot.

A large Swedish study of 100,000 women found that using AI to assist radiologists reading mammograms reduced the rate of aggressive "interval" breast cancers by 12%. CBC News reports: For the study -- published in Thursday's issue of the medical journal The Lancet -- more than 100,000 women had mammography screenings. Half were supported by AI and the rest had their mammograms reviewed by two different radiologists, a standard practice in much of Europe known as double reading. It is not typically used in Canada, where usually one radiologist checks mammograms. The study looked at the rates of interval cancer, the term doctors use for invasive tumors that appear between routine mammograms. They can be harder to detect and studies have shown that they are more likely to be aggressive with a poorer prognosis. The rate of interval cancers decreased by 12 percent in the groups where the AI screening was implemented, the study showed. [...] Throughout the two-year study, the mammograms that were supported by AI were triaged into two different groups. Those that were determined to be low risk needed only one radiologist to examine them, while those that were considered high risk required two. The researchers reported that numerically, the AI-supported screening resulted in 11 fewer interval cancers than standard screening (82 versus 93, or 12 per cent). "This is really a way to improve an overall screening test," [said lead author, Dr. Kristina Lang]. She acknowledged that while the study found a decrease in interval cancer, longer-term studies are needed to find out how AI-supported screening might impact mortality rates. The screenings for the study all took place at one centre in Sweden, which the researchers acknowledged is a limitation. Another is that the race and ethnicity of the participants were not recorded. The next step, Lang said, will be for Swedish researchers to determine cost-effectiveness.

Read more of this story at Slashdot.

For decades, researchers have noted that cancer and Alzheimer's disease are rarely found in the same person, fuelling speculation that one condition might offer some degree of protection from the other. Nature: Now, a study in mice provides a possible molecular solution to the medical mystery: a protein produced by cancer cells seems to infiltrate the brain, where it helps to break apart clumps of misfolded proteins that are often associated with Alzheimer's disease. The study, which was 15 years in the making, was published on 22 January in Cell and could help researchers to design drugs to treat Alzheimer's disease. "They have a piece of the puzzle," says Donald Weaver, a neurologist and chemist at the Krembil Research Institute at the University of Toronto in Canada, who was not involved in the study. "It's not the full picture by any stretch of the imagination. But it's an interesting piece." [...] A 2020 meta-analysis of data from more than 9.6 million people found that cancer diagnosis was associated with an 11% decreased incidence of Alzheimer's disease. It has been a difficult relationship to unpick: researchers must control for a variety of external factors. For example, people might die of cancer before they are old enough to develop symptoms of Alzheimer's disease, and some cancer treatments can cause cognitive difficulties, which could obscure an Alzheimer's diagnosis.

Read more of this story at Slashdot.

A clinical trial found that seniors at high stroke risk who wore an Apple Watch were four times more likely to have hidden heart rhythm disorders detected than those receiving standard care. The researchers noted that over half the time, these smartwatch wearers with heart rhythm problems hadn't shown any symptoms prior to diagnosis. From U.S. News & World Report: Later editions of Apple Watches are equipped with two functions that can help monitor heart health -- photoplethysmography (PPG), which tracks heart rate, and a single-lead electrocardiogram (ECG) that monitors heart rhythm. "Using smartwatches with PPG and ECG functions aids doctors in diagnosing individuals unaware of their arrhythmia, thereby expediting the diagnostic process," said senior researcher Dr. Michiel Winter, a cardiologist at Amsterdam University Medical Center in The Netherlands. "Our findings suggest a potential reduction in the risk of stroke, benefiting both patients and the health care system by reducing costs," Winter said in a news release. [...] Smartwatches are much easier than other wearable devices for detecting irregular heart rhythms [...]. These other means require people to wear sticky leads, carry around bulky monitors or even receive short-term implants. Lead researcher Nicole van Steijn, a doctoral candidate at Amsterdam UMC, noted that wearables that track both the pulse and electrical activity have been around for a while. "However, how well this technology works for the screening of patients at elevated risk for atrial fibrillation had not yet been investigated in a real-world setting,"she said in a news release. The findings have been published in the Journal of the American College of Cardiology.

Read more of this story at Slashdot.

The United States formally withdrew from the World Health Organization on Thursday, making good on an executive order that President Trump issued on his first day in office pledging to leave the international organization that coordinates global responses to public health threats. The New York Times: While the United States is walking away from the organization, a senior official with the Department of Health and Human Services told reporters on Thursday that the Trump administration was considering some type of narrow, limited engagement with W.H.O. global networks that track infectious diseases, including influenza. As a W.H.O. member, the United States long sent scientists from the Centers for Disease Control and Prevention to participate in international decision-making about which strains to include in the flu vaccine. A W.H.O. meeting on next year's vaccine is scheduled for February. The official said the Trump administration would soon disclose how or whether it will participate. On Thursday, the administration said that all U.S. government funding to the organization had been terminated, and that all assigned federal employees and contractors had been recalled from its Geneva headquarters and its offices worldwide.

Read more of this story at Slashdot.

alternative_right shares a report from ScienceAlert: A systematic review of 85 studies has now found good reason to differentiate between 'active' sitting, like playing cards or reading, and 'passive' sitting, like watching TV. [...] "Total sitting time has been shown to be related to brain health; however, sitting is often treated as a single entity, without considering the specific type of activity," explains public health researcher Paul Gardiner from the University of Queensland in Australia. "Most people spend many hours sitting each day, so the type of sitting really matters ... These findings show that small everyday choices -- like reading instead of watching television -- may help keep your brain healthier as you age." Across numerous studies, Gardiner and colleagues found that active sitting activities, like reading, playing card games, and using a computer, showed "overwhelmingly positive associations with cognitive health, enhancing cognitive functions such as executive function, situational memory, and working memory." Meanwhile, passive sitting was most consistently associated with negative cognitive outcomes, including increased risk of dementia. The study was published in the Journal of Alzheimer's Disease.

Read more of this story at Slashdot.

An anonymous reader shares a report: Moderna does not plan to invest in new late-stage vaccine trials because of growing opposition to immunizations from U.S. officials, CEO Stephane Bancel said in an interview with Bloomberg TV on Thursday. "You cannot make a return on investment if you don't have access to the U.S. market," Bancel told Bloomberg TV on the sidelines of the World Economic Forum in Davos. Bancel said regulatory delays and little support from the authorities make the market size "much smaller."

Read more of this story at Slashdot.

An anonymous reader quotes a report from the New York Times: Weight-loss drugs like Ozempic have transformed millions of lives with easily administered treatments and quick results. Now it turns out the dropped pounds may have a surprising perk for airlines, too: lower fuel costs, as slimmer passengers lighten their aircraft's loads. According to a study published last week by Jefferies, a financial services firm, the four largest U.S. carriers -- American Airlines, Delta Air Lines, Southwest Airlines and United Airlines -- could together save as much as $580 million per year on fuel thanks to weight-loss drugs, known as GLP-1s. One in eight U.S. adults said they were taking a GLP-1 in a November survey published by KFF, a nonprofit health research group. Fuel is among airlines' largest expenses. The Jefferies study estimates that the four airlines will together consume 16 billion gallons of fuel in 2026 at a total cost of $38.6 billion, nearly 20 percent of their total expenses. The savings from skinnier passengers would amount to just 1.5 percent of fuel costs. But airlines and pilots must scrutinize even the smallest changes to a plane's weight and balance, and a lighter payload means each jet burns less fuel to generate the thrust necessary to fly. Investors could also stand to benefit: The researchers estimated that a 2 percent reduction in aircraft weight could boost earnings per share by about 4 percent. "Please note savings are before any lost snack sales," the Jefferies analysts added.

Read more of this story at Slashdot.

Many people who stop using weight loss drugs will return to their previous weight within two years, a new review of existing research has found. CNN adds: This rate of weight regain is significantly faster than that seen in those who have lost weight by changing other lifestyle factors, such as diet and exercise, rather than relying on GLP-1 medications, researchers from the University of Oxford report in a paper published Wednesday in The BMJ journal. GLP-1, which stands for glucagon-like peptide-1, is a hormone naturally made by the body that helps signal to the brain and the gut that it's full and doesn't need to eat any more. Weight loss drugs mimic the action of this hormone by increasing the secretion of insulin to lower blood sugar. They also slow the movement of food through the digestive tract, which helps people feel full more quickly and for longer, and they work in the brain to reduce appetite.

Read more of this story at Slashdot.

An anonymous reader quotes a report from DealBook: Fifteen years ago, Daniel Ek broke into America's digital-content wars with his streaming music start-up, Spotify, which has turned into a publicly traded company with a $110 billion market value. Now he and his business partner, the Swedish entrepreneur Hjalmar Nilsonne, aim to crack a higher-stakes consumer market: American health care. The pair plan to bring Neko Health, the health tech start-up they founded in 2018, to New York this spring, DealBook is first to report. Mr. Ek and Mr. Nilsonne hope to capitalize on the growing number of prevention-minded Americans who are hungry to track their biometric data. Whether through wearables like Oura rings or more intensive screenings, consumers are turning to technology to improve their health and help spot the early onset of some big killers, including cardiovascular and metabolic diseases. The United States will be the third market, after Sweden and Britain, for Neko Health, which offers full-body diagnostic scans and is valued at roughly $1.7 billion. [...] Mr. Nilsonne and Mr. Ek said Neko Health's big aim was to change the health care model, in which spending across much of the developed world skyrockets but longevity gains have stalled. They want to make their noninvasive scans as routine as an annual checkup. The company, which advertises its service as "a health check for your future self," did not say what the U.S. scans would cost. But in Stockholm, an hourlong visit at one of its clinics costs 2,750 Swedish krona (about $300). Prenuvo's and Ezra's most comprehensive scans can cost $3,999. [...] Neko Health's technology differs from that of many of its U.S. rivals. It does not use M.R.I. or X-rays, instead relying on scores of sensors and cameras and a mix of proprietary and off-the-shelf technologies to measure heart function and circulation, and to photograph and map every inch of a patient's body looking for cancerous lesions. At the moment, the company's biggest challenge is scaling. [...] Mr. Nilsonne said Neko Health scans have detected the early onset of diseases or serious medical conditions for thousands of its patients. But the medical community is divided on the need for proactive screening technologies. The fear is that mass adoption could spur a wave of false positives and send healthy people to seek follow-up medical advice, overwhelming an already swamped health care system. Mr. Ek and Mr. Nilsonne believe they have built a better solution. And now they're ready to test it in the U.S. market.

Read more of this story at Slashdot.

Doctors say they have achieved the previously impossible -- restoring sight and preventing blindness in people with a rare but dangerous eye conditon called hypotony. From a report: Moorfields hospital in London is the world's first dedicated clinic for the disorder and seven out of eight patients given the pioneering treatment have responded to the therapy, a pilot study shows. One of them -- the first-ever -- is Nicki Guy, 47, who is sharing her story exclusively with the BBC. She says the results are incredible: "It's life-changing. It's given me everything back. I can see my child grow up. "I've gone from counting fingers and everything being really blurry to being able to see." Currently, she can see and read most lines of letters on an eye test chart. She is one line away from what is legally required for driving - a massive change from being partially sighted, using a magnifying glass for anything close up and having to navigate around the house and outside largely using memory. "If my vision stays like this for the rest of my life it would be absolutely brilliant. I may not ever be able to drive again but I'll take that!" she says. With hypotony, pressure within the eyeball becomes dangerously low, leading it to cave in on itself.

Read more of this story at Slashdot.

Microbiology had its golden age in the late nineteenth century, when researchers identified the bacterial causes of tuberculosis, cholera, typhoid, and a dozen other diseases in rapid succession. Antibiotics had theirs in the mid-twentieth century. Both booms eventually slowed. Vaccine development, by contrast, appears to be speeding up -- and the most productive era may still lie ahead, Works in Progress writes in a story. In the first half of the 2020s alone, researchers delivered the first effective vaccines against four different diseases: Covid-19, malaria, RSV and chikungunya. No previous decade matched that output. The acceleration rests on infrastructure that took two centuries to assemble. Edward Jenner's 1796 smallpox vaccine was a lucky accident he didn't understand. Louis Pasteur needed ninety years to turn that luck into systematic methods -- attenuation and inactivation -- that could be applied to other diseases. Generations of scientists then built the supporting machinery: Petri dishes for bacterial culture, techniques to keep animal cells alive outside the body, bioreactors for industrial production, sterilization and cold-chain logistics. Those tools have now compounded. Cryo-electron microscopy reveals viral proteins atom by atom, a capability that directly enabled the RSV vaccine after earlier attempts failed. Genome sequencing costs collapsed from roughly $100 million per human genome in 2001 to under $1,000 by 2014, according to data from the National Human Genome Research Institute. The mRNA platform, refined through work by Katalin Kariko, Drew Weissman, and others, allows vaccines to be redesigned in weeks rather than years. The trajectory suggests more breakthroughs are possible. Whether they arrive depends on continued investment, however.

Read more of this story at Slashdot.

sinij shares a news release from the Utah Department of Commerce: The state of Utah, through the Utah Department of Commerce's Office of Artificial Intelligence Policy, today announced a first-of-its-kind partnership with Doctronic, the AI-native health platform, to give patients with chronic conditions a faster, automated way to renew medications. This agreement marks the first state-approved program in the country that allows an AI system to legally participate in medical decision-making for prescription renewals, an emerging model that could reshape access to care and ultimately improve care outcomes. Politico provides additional context in its reporting: In data shared with Utah regulators, Doctronic compared its AI system with human clinicians across 500 urgent care cases. The results showed the AI's treatment plan matched the physicians' 99.2 percent of the time, according to the company. "The AI is actually better than doctors at doing this," said Dr. Adam Oskowitz, Doctronic co-founder and an associate professor of surgery at the University of California San Francisco. "When you go see a doctor, it's not going to do all the checks that the AI is doing." Oskowitz said the AI is designed to err on the side of safety, automatically escalating cases to a physician if there's any uncertainty. Human doctors will also review the first 250 prescriptions issued in each medication class to validate the AI's performance. Once that threshold is met, subsequent renewals in that class will be handled autonomously. The company has also secured a one-of-a-kind malpractice insurance policy covering an AI system, which means the system is insured and held to the same level of responsibility as a doctor would be. Doctronic also runs a nationwide telehealth practice that directs patients to doctors after an AI consultation. In Utah, patients who use the system will visit a webpage that verifies they are physically in the state. Then the system will pull the patient's prescription history and offer a list of medications eligible for renewal. The AI walks the patient through the same clinical questions a physician would ask to determine whether a refill is appropriate. If the system clears the renewal, the prescription is sent directly to a pharmacy. The program is limited to 190 commonly prescribed medications. Some medications -- including pain management and ADHD drugs as well as injectables -- are excluded for safety reasons.

Read more of this story at Slashdot.

Scientists at Melbourne's Peter Doherty Institute for Infection and Immunity are working on a Crispr-based treatment -- delivered as a nasal spray or injection -- that could stop influenza infections by targeting the virus's RNA and disrupting its ability to replicate inside human cells. The approach uses the Cas13 enzyme, a lesser-known cousin of the DNA-cutting Cas9, which can be engineered to seek out conserved regions of influenza's genetic code that are found in virtually all flu strains and are crucial to the virus's survival. The delivery mechanism would use lipid nanoparticles to ferry two molecular instructions to flu-infected cells in the respiratory tract: an mRNA that tells cells to produce Cas13 and a guide RNA that directs the enzyme to specific parts of the influenza virus's code. Cas13 then cuts the viral RNA and effectively stops the infection at the genetic level, Sharon Lewin, the infectious diseases physician leading the project, told Wired. Early safety testing at Harvard's Wyss Institute used a "lung on a chip" model to examine whether human cells producing Cas13 could fight off flu strains including H1N1 and H3N2. The institute's founding director Donald Ingber says the studies showed no off-target effects.

Read more of this story at Slashdot.

An anonymous reader shared this report from the Independent: Candida auris, a type of invasive yeast that can cause deadly infections in people with weakened immune systems, has infected at least 7,000 people [in 2025] across 27 U.S. states, according to data from the Centers for Disease Control and Prevention. The fungus, which can spread easily in healthcare settings such as hospitals and nursing homes, is gaining virulence and spreading at an "alarming" rate, the CDC says. Some strains of the fungus are particularly troublesome — and even considered a superbug — because they're resistant to all types of antibiotics used to treat fungal infections, The Hill reports. While healthy people may be able to fight off the infection on their own, the fungus can be deadly, especially in healthcare settings, where it can quickly spread amongst a vulnerable population. "If you get infected with this pathogen that's resistant to any treatment, there's no treatment we can give you to help combat it. You're all on your own," Melissa Nolan, an assistant professor of epidemiology and biostatistics at the University of South Carolina, told Nexstar... A recent study found that Candida auris is gaining virulence and spreading rapidly, not just in the U.S., but also globally. Candida auris has already been found in at least 61 countries on six continents. Some context from Newsweek: There are strategies available to combat Candida auris infection. While the superbug can develop ways to evade the immune response, vaccination and treatment strategies are possible, but researchers would like them to be strengthened. Four classes of antifungal drugs are currently available, with varying degrees of efficacy, and three new drugs are currently in trials or at newly approved stages

Read more of this story at Slashdot.

The Wall Street Journal reports that a growing number of tech startups are stocking offices with free nicotine pouches as founders and employees chase sharper focus and stamina in hyper-competitive AI-era work environments. The Wall Street Journal reports: Earlier this year, two nicotine startups -- Lucy Nicotine and Sesh -- made branded vending machines filled with flavored products for analytics company Palantir Technologies. Both machines are in the company's Washington, D.C., offices. The pouches are free for employees and guests over the age of 21, a spokeswoman for Palantir said. Palantir pays to stock the nicotine products. Alex Cohen, a startup founder based in Austin, Texas, said he was first exposed to nicotine pouches in the workplace after seeing tins of Zyns on the desks of his software engineers. His company, Hello Patient, makes AI-powered healthcare-communication software. "They were very productive, so I thought maybe there's something here," he said. Those engineers soon asked him if he could buy it for the office. Cohen said he initially bought the nicotine pouches as a joke for social media. He posted a picture of a drawer in his startup's office filled with nicotine pouches made by different brands with the caption, "We're hiring." "Then, I accidentally got addicted," said Cohen. He said he uses around two to three pouches a day. His go-to flavors are mango or minty. Cohen said he has attention-deficit/hyperactivity disorder, or ADHD, and he has found that the pouches can provide a quick productivity boost. "It helps with reining in my focus because it is a stimulant," he said. Today, Hello Patient has a nicotine-pouch fridge in its office kitchen.

Read more of this story at Slashdot.

A study by a Singapore government agency has found that children exposed to high levels of screen time before age two showed brain development changes linked to slower decision-making and higher anxiety in adolescence, adding to concerns about early digital exposure. From a report: The study was conducted by a team within the country's Agency for Science, Technology and Research and the National University of Singapore, and published in The Lancet's eBioMedicine open access journal. It tracked 168 children for more than a decade, and conducted brain scans on them at three time points. Heavier screen exposure among very young children was associated with "accelerated maturation of brain networks" responsible for vision and cognitive control, the study found. The researchers suggested this may have been the result of "intense sensory stimulation that screens provide." They found that screen time measured at ages three and four, however, did not show the same effects. Those children with "altered brain networks" took longer to make decisions when they were 8.5, and also had higher anxiety symptoms at age 13, the study said.

Read more of this story at Slashdot.